whole human genome mirna microarray v. 3  (Agilent technologies)

Journal: Annals of Indian Academy of Neurology

Article Title: Clinical Application of Circulating MicroRNAs in Parkinson's Disease: The Challenges and Opportunities as Diagnostic Biomarker

doi: 10.4103/aian.AIAN_440_19

Figure Lengend Snippet: Proposed candidate miRNAs in various body fluids of PD compared to healthy controls

Article Snippet: Khoo et al ., 2012 , Plasma , , TRI reagent RT-blood protocol (Molecular Research Center, Cincinnati, OH) , , Saint Mary’s Health Care Hauenstein Parkinson’s Center (SMHCPC), Grand Rapids, MI, USA , PD-32 HC-32 , Agilent whole human genome miRNA microarray v. 3 [Agilent, Santa Clara, CA)] Validated with StepOnePlus RT-PCR system ]Applied Biosystems, Foster City, CA] , miR-222, miR-626, and miR-505 , , ( ) .

Techniques: Isolation, Derivative Assay, TLDA Assay, Spectrophotometry, Electrophoresis, Hybridization, Real-time Polymerase Chain Reaction, Microarray, Quantitative RT-PCR, Fluorescence, Protein Extraction, Reverse Transcription Polymerase Chain Reaction, Sequencing, Next-Generation Sequencing

Journal: International Journal of Molecular Sciences

Article Title: Role of MicroRNAs in Parkinson’s Disease

doi: 10.3390/ijms20225649

Figure Lengend Snippet: Summary of 15 miRNAs reported to be dysregulated in the brain/neuronal model(s), cerebrospinal fluid (CSF) and blood.

Article Snippet: , hsa-miR-200a , ↑ , - , - , Plasma from 32 PD patients vs. 32 controls , Agilent whole human genome miRNA microarray v.3 , [ ] .

Techniques: RNA Sequencing Assay, Isolation, TLDA Assay, Real-time Polymerase Chain Reaction, Microarray, Transgenic Assay, Expressing, Next-Generation Sequencing